Harmony Biosciences Holdings, Inc. reiterated revenue guidance for the year 2024. For the year, the company reiterated net product revenue of $700 million - $720 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.45 USD | -3.43% |
|
-3.40% | +8.83% |
Feb. 03 | BofA Adjusts Price Target on Harmony Biosciences to $31 From $32 | MT |
Jan. 28 | Harmony Biosciences Holdings Insider Sold Shares Worth $551,575, According to a Recent SEC Filing | MT |

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HRMY Stock
- News Harmony Biosciences Holdings, Inc.
- Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for the Year 2024